SCHEMBL8400352

SCHEMBL8400352

Cc1cccc2cc(-c3nc(C4CCCCC4)n4ccnc(N)c34)[nH]c12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 3/20 0.66
PIK3CA P42336 1/20 0.64
PIK3CB P42338 1/20 0.64
MTOR P42345 1/20 0.64
PIK3CG P48736 1/20 0.64
PRKDC P78527 1/20 0.64
RICTOR Q6R327 1/20 0.64
RPTOR Q8N122 1/20 0.64
MAPKAP1 Q9BPZ7 1/20 0.64
MLST8 Q9BVC4 1/20 0.64
TNK2 Q07912 10/20 0.58
RAF1 P04049 2/20 0.54
SRC P12931 2/20 0.54
IGF1R P08069 5/20 0.54
PDPK1 O15530 1/20 0.53
ABL1 P00519 1/20 0.53
EGFR P00533 1/20 0.53
INSR P06213 1/20 0.53
KDR P35968 1/20 0.53
MAP2K1 Q02750 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6942571 0.97 FGFR1 (0.69) FGFR1PIK3CAPIK3CBMTORPIK3CG
SCHEMBL7999510 0.89 PIK3CA (0.66) FGFR1PIK3CAPIK3CBMTORPIK3CG
SCHEMBL12708863 0.89 PIK3CA (0.80) FGFR1PIK3CAPIK3CBMTORPIK3CG
SCHEMBL6943372 0.88 PIK3CA (0.82) FGFR1PIK3CAPIK3CBMTORPIK3CG
SCHEMBL14536899 0.88 FGFR1 (0.63) FGFR1PIK3CAPIK3CBMTORPIK3CG
SCHEMBL8232831 0.87 PIK3CA (0.64) FGFR1PIK3CAPIK3CBMTORPIK3CG
SCHEMBL13527341 0.87 PIK3CA (0.67) FGFR1PIK3CAPIK3CBMTORPIK3CG
SCHEMBL8406228 0.86 PIK3CA (0.59) FGFR1PIK3CAPIK3CBMTORPIK3CG
SCHEMBL14536968 0.86 PIK3CA (0.61) FGFR1PIK3CAPIK3CBMTORPIK3CG
SCHEMBL12328132 0.86 PIK3CA (0.58) FGFR1PIK3CAPIK3CBMTORPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090163468-A1 Fused Bicyclic mTor Inhibitors OSI PHARMACEUTICALS, INC. 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163468-A1 Fused Bicyclic mTor Inhibitors MTOR, RICTOR, MAPKAP1 FGFR1 147/4885PIK3CA 25/4885PIK3CB 92/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.